DBVT
DBV Technologies S.A.
DBV Technologies S.A. (DBVT) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 42.8, with 0/3 trend checks passing.
DBVT with MA50 and MA200
Key levels & signals
DBV Technologies S.A. (DBVT) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $15.71, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 10.4% and below the 200-day moving average by 13.5%.
DBVT currently has an RSI reading of 42.8, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
For traders reviewing DBVT next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About DBV Technologies S.A.
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Learn the indicators behind this page
More stock opportunities
Common questions about DBVT
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.